The MyMRD is a hotspot panel that detects all classes of variants identified in a precisely defined set of targets that commonly drive myeloid malignancies including AML, MPN and MDS. It can detect SNV, indels and translocations to the genomic basepair, giving unparalleled precision and detection of low level mutations in patients. Testing with MyMRD allows for studying important mutations in known genes implicated in the causation, prognosis, and reoccurrence of myeloid disorders.
Minimal residual disease (MRD) detection has proven to be useful in the clinical management of patients with leukemia and can facilitate the development of new therapies. Patients with myeloid neoplasms are typically divided into different prognostic groups based upon both cytogenetics and traditional molecular profiles1; however, this may not reflect the heterogeneity of disease2 that can be exploited using MRD assessment.
Cancer heterogeneity poses several challenges to monitor MRD in patients. Additionally, patient sample is usually very limited, and therefore, serial testing is many times not a viable option. Thus, the development of a sensitive and reliable assay to detect several mutations within one sample represents a significant advancement in guiding treatment decisions. With the MyMRD assay, one sample is enough to characterize at least one driving mutation in 90%-95% of all AMLs.